InVivo Biosystems: Funding, Investors & Team (Sep 2026)
InVivo Biosystems is a biotechnology company that offers genome editing and in vivo analytical services to speed up drug discovery and development. They specialize in creating customized genome-edited models of C. elegans and zebrafish to aid research in neurological, metabolic, and rare monogenic diseases. The company was formed from the merger of NemaMetrix and Knudra Transgenics and has developed unique technologies, such as the RapidGen™ preclinical platform, to connect cell culture and rodent models. This platform allows for early compound screening, toxicity testing, and efficacy analysis, providing valuable biological data for drug development decisions. InVivo Biosystems caters to pharmaceutical, nutraceutical, biotechnology companies, and academic research institutions, offering services like CRISPR genome editing, zebrafish toxicity testing, and compound efficacy testing. The company has multiple global patents for its genome editing technologies and continues to lead in preclinical development innovation.
InVivo Biosystems has raised $3.0M across 2 funding rounds on record, the most recent an undisclosed round announced in Apr 2025.
InVivo Biosystems Company Profile and Key Stats
Latest funding round on record: Apr 2025.
InVivo Biosystems Funding Rounds
1 of 2 rounds was announced without a disclosed amount and is excluded from the total.
InVivo Biosystems raised $3.0M in an undisclosed round announced in Jan 2024.
1.3 years later, an undisclosed round was announced in Apr 2025 with no disclosed amount.
InVivo Biosystems Founders and Leadership Team
Contact details for the InVivo Biosystems team: 1 of 2 have an email address on file.
Start 14-day free trial →InVivo Biosystems Funding Compared to Other Biotechnology Startups
Funded Startups Like InVivo Biosystems in Biotechnology and Eugene
Companies Similar to InVivo Biosystems
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
InVivo Biosystems Funding FAQs
What does InVivo Biosystems do?
InVivo Biosystems is a biotechnology company that offers genome editing and in vivo analytical services to speed up drug discovery and development. They specialize in creating customized genome-edited models of C. elegans and zebrafish to aid research in neurological, metabolic, and rare monogenic diseases. The company was formed from the merger of NemaMetrix and Knudra Transgenics and has developed unique technologies, such as the RapidGen™ preclinical platform, to connect cell culture and rodent models. This platform allows for early compound screening, toxicity testing, and efficacy analysis, providing valuable biological data for drug development decisions. InVivo Biosystems caters to pharmaceutical, nutraceutical, biotechnology companies, and academic research institutions, offering services like CRISPR genome editing, zebrafish toxicity testing, and compound efficacy testing. The company has multiple global patents for its genome editing technologies and continues to lead in preclinical development innovation.
How much funding has InVivo Biosystems raised?
InVivo Biosystems has raised $3.0M across 2 rounds on record.
When did InVivo Biosystems last raise funding?
InVivo Biosystems' most recent funding round on record was announced in Apr 2025. The amount was not disclosed.
Who founded InVivo Biosystems?
FundedIQ lists Janis Weeks (Founder), Matt Beaudet (Founder) at InVivo Biosystems.
Where is InVivo Biosystems headquartered?
InVivo Biosystems is based in Eugene, Oregon, United States.
How many employees does InVivo Biosystems have?
InVivo Biosystems is in the 51-100 employee band.
About FundedIQ's InVivo Biosystems Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for InVivo Biosystems is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.